ATE259779T1 - Formoterol-polymorphe - Google Patents

Formoterol-polymorphe

Info

Publication number
ATE259779T1
ATE259779T1 AT99968848T AT99968848T ATE259779T1 AT E259779 T1 ATE259779 T1 AT E259779T1 AT 99968848 T AT99968848 T AT 99968848T AT 99968848 T AT99968848 T AT 99968848T AT E259779 T1 ATE259779 T1 AT E259779T1
Authority
AT
Austria
Prior art keywords
formoterol
optically pure
polymorphos
disclosed
benzeneethanamine
Prior art date
Application number
AT99968848T
Other languages
English (en)
Inventor
Yun Gao
Kevin Q Fang
Robert Hett
Martin P Redmon
Chris Hugh Senanayake
Stephen Alan Wald
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE259779T1 publication Critical patent/ATE259779T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C07C217/86—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT99968848T 1998-05-21 1999-05-20 Formoterol-polymorphe ATE259779T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/083,010 US6040344A (en) 1996-11-11 1998-05-21 Formoterol process
PCT/US1999/025371 WO2000021487A2 (en) 1998-05-21 1999-05-20 Formoterol polymorphs

Publications (1)

Publication Number Publication Date
ATE259779T1 true ATE259779T1 (de) 2004-03-15

Family

ID=22175359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968848T ATE259779T1 (de) 1998-05-21 1999-05-20 Formoterol-polymorphe

Country Status (10)

Country Link
US (2) US6040344A (de)
EP (1) EP1082293B1 (de)
JP (1) JP2002527364A (de)
AT (1) ATE259779T1 (de)
CA (1) CA2333004C (de)
DE (1) DE69914898T2 (de)
DK (1) DK1082293T3 (de)
ES (1) ES2216632T3 (de)
PT (1) PT1082293E (de)
WO (1) WO2000021487A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
CN1391475A (zh) * 1999-09-13 2003-01-15 布里奇药品有限公司 酮替芬的旋光异构体及其治疗学上的活性代谢产物
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6666774B2 (en) * 2000-07-27 2003-12-23 Attitude Technology, Inc. Billiard equipment
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7659225B2 (en) * 2001-09-17 2010-02-09 Basf Catalysts Llc Precious metal catalyst for debenzylation
US6992037B2 (en) * 2001-09-17 2006-01-31 Engelhard Corporation Precious metal catalyst for debenzylation
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
ES2779273T3 (es) * 2002-03-01 2020-08-14 Chiesi Farm Spa Formulación superfina de formoterol
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
KR101166955B1 (ko) 2002-12-10 2012-07-19 선오비온 파마슈티컬스 인코포레이티드 레발부테롤 염
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
EP1587482A4 (de) * 2003-01-31 2010-08-25 Technion Res & Dev Foundation Entzündungshemmende zusammensetzungen und ihre verwendungen
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
JP4616264B2 (ja) * 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP5618452B2 (ja) 2003-09-16 2014-11-05 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングＴａｋｅｄａ ＧｍｂＨ 呼吸器疾患の治療のためのシクレソニドの使用
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1730104A1 (de) * 2004-04-02 2006-12-13 Glaxo Group Limited Chemisches verfahren und neue kristalline form
WO2005097095A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105065A2 (en) * 2004-05-05 2005-11-10 Renopharm Ltd. Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
BRPI0511695A (pt) * 2004-06-03 2008-01-08 Theravance Inc agonistas de receptor (beta)2 adrenérgico diamina
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
EP1786762A2 (de) 2004-09-10 2007-05-23 Theravance, Inc. Amidin-substituierte arylanilinverbindungen
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8501994B2 (en) 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer
US7718822B2 (en) * 2007-08-28 2010-05-18 Sepracor Inc. Carbamate Stereoisomer
CN101393186A (zh) * 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 一种hplc法分离分析酒石酸福莫特罗手性异构体的方法
AU2009241628A1 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2262479A2 (de) * 2008-02-28 2010-12-22 Actavis Group PTC ehf. Amorphes arformoterol l-(+)-tartrat
US9029421B2 (en) * 2008-06-02 2015-05-12 Cipla Limited Process for the synthesis of arformoterol
US20090306215A1 (en) * 2008-06-10 2009-12-10 Protia, Llc Deuterium-enriched arformoterol
US20110313199A1 (en) * 2008-12-26 2011-12-22 Actavis Group Ptc Ehf processes for preparing substantially pure arformoterol and its intermediates
CN102405044A (zh) * 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
CN101531597B (zh) * 2009-04-01 2013-03-06 杭州师范大学 3-硝基-4-苄氧基-α-溴代苯乙酮的新型合成方法
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111926T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN101921200B (zh) * 2009-06-16 2014-01-15 上海医药工业研究院 一种n-苄基-1-(4-甲氧基苯基)-2-丙胺的制备方法
ES2557553T3 (es) 2009-07-15 2016-01-27 Theravance Biopharma R&D Ip, Llc Forma de base libre cristalina de un compuesto de bifenilo
US20110229437A1 (en) * 2009-09-17 2011-09-22 Mutual Pharmaceutical Company, Inc. Method of Treating Asthma with Antiviral Agents
EP2348013A1 (de) 2010-01-25 2011-07-27 Inke, S.A. Verfahren zur Herstellung von Zwischenverbindungen von Arformoterol
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
CN102199098B (zh) * 2010-03-22 2013-07-31 中山大学 一种合成(r)-n-苄基-1-(4-甲氧基苯基)-2-丙胺的方法及其应用
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES3034958T3 (en) 2010-08-27 2025-08-27 Univ Southern California Pharmaceutical compositions comprising derivatives of perillyl alcohol
US9211269B2 (en) 2010-12-17 2015-12-15 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
ES2677714T3 (es) 2012-03-12 2018-08-06 Laboratorios Lesvi S.L. Nueva forma polimórfica de un agonista del adrenorreceptor beta-2 de acción prolongada
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US9700558B2 (en) 2013-03-15 2017-07-11 Verona Pharma Plc Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
WO2014184756A2 (en) * 2013-05-17 2014-11-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of arformoterol or salt thereof
PE20160155A1 (es) 2013-05-22 2016-04-01 Pearl Therapeutics Inc Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
CN103772289B (zh) * 2014-01-03 2016-02-17 湖南迪诺制药有限公司 合成塞克硝唑的方法及塞克硝唑
DK3231444T3 (da) 2014-05-12 2020-03-16 Verona Pharma Plc Ny behandling
JP6674957B2 (ja) 2015-02-12 2020-04-01 ネオンク テクノロジーズ インク． ペリリルアルコール誘導体を含む医薬組成物
WO2018102412A1 (en) 2016-11-30 2018-06-07 Neonc Technologies, Inc. A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
DK3749291T3 (da) 2018-02-08 2024-04-08 Univ Southern California Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
CN110627673B (zh) * 2018-06-22 2023-04-07 上海天慈中商药业有限公司 一种福莫特罗关键中间体的制备方法
US11642372B2 (en) * 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
CN111909049B (zh) * 2020-09-03 2023-04-25 扬州中宝药业股份有限公司 一种酒石酸阿福特罗精制的方法
CN112745234A (zh) * 2020-12-31 2021-05-04 河北化工医药职业技术学院 利用非环原子上连接羟基的单环不饱和化合物制备双手性中心药物的方法
CR20240064A (es) 2021-07-09 2024-09-02 Astrazeneca Pharmaceuticals Lp Composiciones, métodos y sistemas para la administración de fármacos en aerosol
US20250057764A1 (en) 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
ES2005492A6 (es) * 1987-12-23 1989-03-01 Lasa Lab Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i).
ES2031407A6 (es) * 1988-10-05 1992-12-01 Lasa Lab Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida".
SE8901060D0 (sv) * 1989-03-28 1989-03-28 Draco Ab New compounds
SE9003057D0 (sv) * 1990-09-26 1990-09-26 Astra Ab New process
WO1997025311A1 (en) * 1996-01-10 1997-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
ATE219047T1 (de) * 1996-11-11 2002-06-15 Sepracor Inc Verfahren zur herstellung von optisch reinen isomeren des formoterols
EP1021172B1 (de) * 1997-10-08 2002-04-10 Sepracor, Inc. Dosierungsform zur verabreichung von aerosolen

Also Published As

Publication number Publication date
DK1082293T3 (da) 2004-06-21
DE69914898T2 (de) 2004-12-09
EP1082293A2 (de) 2001-03-14
US6268533B1 (en) 2001-07-31
EP1082293B1 (de) 2004-02-18
US6040344A (en) 2000-03-21
CA2333004C (en) 2009-08-18
ES2216632T3 (es) 2004-10-16
PT1082293E (pt) 2004-07-30
CA2333004A1 (en) 2000-04-20
WO2000021487A2 (en) 2000-04-20
WO2000021487A3 (en) 2000-07-13
JP2002527364A (ja) 2002-08-27
DE69914898D1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE259779T1 (de) Formoterol-polymorphe
PT938467E (pt) Processo para a preparacao de isomeros opticamente puros de formoterol
RU94042903A (ru) 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения, фармкомпозиция
CA2200707A1 (en) Novel prostaglandin synthase inhibitors
RU94036748A (ru) Церамиды, способ их получения, композиция на их основе и способ гидратирующей обработки кожи или волос
EP0863755A4 (de) Antithrombotische diamine
PT82127B (pt) Processo para a preparacao de carbamatos de fenilo
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
DE69738154D1 (de) Optische auflösung von methylphenidat mittels 0,0'-bisaroyl-weinsäuren
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PT1349828E (pt) Processo para a preparacao de isomeros de salutamol
DK0938584T3 (da) Fremgangsmåde til fremstilling af (S)-eller (R)-3,3,3-trifluor-2-hydroxy-2-methylpropionsyre
NO20053089L (no) Carbamidsyreestere med anticolinergisk virkning.
AU3042497A (en) Vaccine containing a peroxiredoxin and/or a beta-tubulin
ES2196783T3 (es) Nuevo procedimiento de preparacion de la fexofenadina.
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
ID27440A (id) Proses untuk menyiapkan penengah-penengah
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
RU94036762A (ru) Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina
TW332205B (en) A process for making a clinically efficacious HIV protease inhibitor eliminates one step in its synthesis, by an alternative convergent synthesis using 2(S)-4-picolyl-2-piperazine-t-butyl-carboxamide as an intermediate.
ATE295728T1 (de) Herstellung von 3-fluoroxindolderivaten
BR9906931A (pt) Triazepinonas, processo para sua preparação e sua aplicação terapêutica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082293

Country of ref document: EP